ARTICLE | Clinical News
SR Pharma reports Phase III data
July 25, 2001 7:00 AM UTC
SR Pharma (LSE:SPA) said data from its pan-European Phase III trial showed improvements in the quality of life of 183 non-small cell lung cancer patients given SRL172 in combination with standard anti...